Immuneering Corp (IMRX)
AI stock analysis · as of Jun 1, 2026
Loading microstructure…
Immuneering (IMRX) is a pre-revenue, single-asset clinical-stage oncology company developing atebimetinib (IMM-1-104), a dual-MEK inhibitor showing striking Phase 2a survival data in first-line metastatic pancreatic cancer (64% OS at 12 months vs. 35% for standard of care; 17.3-month median OS). The core investment question is whether the cross-trial Phase 2a signal will hold in a randomized Phase 3 (MAPKeeper 301, starting mid-2026), and whether the company can fund itself through readout without catastrophic dilution. At $4.43 and a ~$286M market cap against $129M cash and no debt, this is a binary clinical bet with optionality across MAPK-driven tumors.
valuationExpensive on conventional metrics (negative EV/EBITDA -3.7x, P/B 1.3x, -11.6% FCF yield) but appropriately valued as a clinical option — at $286M market cap net of $125M cash, enterprise value is ~$161M for a drug with a credible path to a multi-billion-dollar PDAC indication if Phase 3 succeeds.
This analysis is from Jun 1, 2026. Want the latest on IMRX, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Phase 2a interim data are clinically meaningful in a notoriously refractory cancer: 64% OS at 12 months vs. 35% MPACT benchmark in first-line PDAC, with median OS of 17.3 months at 13.4-month follow-up — a magnitude that, if replicated, would be practice-changing
- · Differentiated tolerability (mostly Grade 1-2 AEs, no Grade 5 TEAEs at 320 mg) addresses the chronic dosing problem that has historically limited MEK inhibitors in combination regimens
- · Strong balance sheet relative to burn: $129M cash, ~$45-56M annual burn, and management commentary suggesting runway into 2029 reduces near-term financing pressure ahead of Phase 3 initiation
- · Pipeline optionality via partnered combination trials with Regeneron (Libtayo) and Eli Lilly (olomorasib) in lung cancer extends the addressable opportunity beyond pancreatic
- · Regulatory tailwinds: three FDA Fast Track designations and Orphan Drug status; analyst consensus is strong-buy with mean target $17 (~285% upside) and Oppenheimer/new coverage at $20
- · Elevated short interest (20.15% of float, 13.09 days to cover) sets up squeeze potential on positive Phase 3 initiation news or ASCO data updates
Bear case
- · Single-asset concentration risk amplified by April 2025 pause of envometinib; atebimetinib failure would be near-terminal for the equity
- · Phase 2a is single-arm, n=34, with cross-trial comparisons to MPACT — historical PDAC trials have repeatedly shown early signals that fail to replicate in randomized settings
- · Phase 3 MAPKeeper 301 does not dose first patient until mid-2026, meaning the pivotal readout is likely 2028+; multiple dilutive raises are nearly certain in the interim (share count already grew from prior periods to 64.7M)
- · Competitive landscape is brutal: Revolution Medicines, BMS/Mirati, Amgen, Merck, AstraZeneca all advancing RAS/MEK programs with vastly greater resources
- · Negative ROE (-43.8%), -$45M FCF, and reliance on ATM programs and private placements (Aventis September 2025) signal ongoing dilution overhang
- · Stock has already round-tripped — 52-week range of $1.66-$10.08 and a -24% single-day move illustrates how violent clinical biotech sentiment swings can be
Catalysts
- · ASCO oral presentation with updated Phase 2a survival data — near-term and high-impact
- · Phase 3 MAPKeeper 301 trial initiation in mid-2026 (first patient dosed)
- · Lung cancer combination data updates from Regeneron (Libtayo) and Lilly (olomorasib) partnerships
- · Potential short squeeze: 20% short float and 13-day cover ratio could amplify upside on positive data
- · Additional FDA regulatory actions (e.g., Breakthrough Designation) or potential partnership/licensing deal on atebimetinib
- · Next earnings on 2026-08-13 with operational and runway updates
Key risks
- · Phase 3 enrollment delays or failure — catastrophic given single-asset dependency
- · Cross-trial Phase 2a signal does not replicate in randomized Phase 3 setting
- · Ongoing equity dilution erodes per-share value even if drug succeeds
- · Competitive read-throughs from larger RAS/MEK programs render atebimetinib commercially marginal
- · CMC/CRO execution risk on combination regimen manufacturing and clinical conduct
What to watch
- · ASCO oral presentation timing and updated median OS readout
- · Cash runway commentary and any new ATM/PIPE activity that signals dilution
- · Phase 3 MAPKeeper 301 IND/protocol updates and enrollment timing confirmation for mid-2026
- · Short interest trajectory — currently 20% of float with 13-day cover
- · Key technical levels: $1.66 (52-week low support), $10.08 (52-week high resistance)
- · Next earnings 2026-08-13 for burn rate and pipeline updates
Key metrics
Price target rationale
Base case $8 assumes Phase 3 initiates on schedule with continued positive Phase 2a updates and modest re-rating to ~$500M market cap, partially offset by dilution. Bull case $15 reflects strong ASCO data, partnership announcement, and short squeeze dynamics approaching street targets. Bear case $2.50 reflects dilutive raise(s), data disappointment, or Phase 3 delay — note 52-week low was $1.66.
On Wall Street's view (mixed): The $17 consensus target (285% upside) reflects risk-adjusted Phase 3 success probability that I think is directionally reasonable given the Phase 2a magnitude, but it likely understates dilution between now and 2028+ readout and may be too aggressive on a 12-month basis given Phase 3 doesn't even start until mid-2026.
Latest filing (10-K)
Immuneering is a cash-burning pre-revenue oncology company betting everything on atebimetinib, a novel MEK inhibitor showing striking early survival data in pancreatic cancer (64% vs. 35% OS at 12 months), with a make-or-break Phase 3 trial set to begin mid-2026.
Immuneering Corporation (IMRX) is a late-stage clinical oncology company developing 'Deep Cyclic Inhibitors' (DCI), a novel class of small-molecule cancer drugs designed to cyclically disrupt tumor signaling pathways rather than chronically suppress them. The company has no approved products and generates no product revenue; it is entirely pre-commercial and funds operations through equity issuances. Its lead asset, atebimetinib (IMM-1-104), is an oral MEK inhibitor in Phase 1/2a trials with a Phase 3 trial (MAPKeeper 301) in first-line pancreatic cancer expected to begin dosing mid-2026.
What the news says · bullish
The dominant storyline for IMRX centers on increasingly compelling clinical data for its pancreatic cancer drug combination, with a 17.3-month median survival result and a standout 27-month progression-free case drawing significant attention ahead of an ASCO oral presentation. Oppenheimer maintained its Outperform rating on the survival data, and a $20 price target from a new analyst adds to the constructive Wall Street backdrop. Insider buying, a cash runway into 2029, and a novel MEK resistance profile further support the bull case. The main counterweight is Piper Sandler's price target cut on launch timing concerns and a prior sharp sell-off in January despite positive data — a reminder that clinical-stage biotech sentiment can be volatile and that execution risk remains real. Coverage is reasonably active for a small-cap name, though it skews heavily toward clinical milestones rather than commercial fundamentals.
This analysis is from Jun 1, 2026. Markets move. Get the current read on IMRX and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.